Collegium Pharmaceutical Inc (COLL)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 70.92% | 52.28% | 58.87% | 63.97% | 34.84% |
| Operating profit margin | 36.30% | 8.31% | 6.89% | 20.00% | -8.03% |
| Pretax margin | 16.47% | -7.20% | -1.32% | 9.81% | -7.68% |
| Net profit margin | 10.47% | -6.24% | 27.95% | 9.52% | -7.68% |
Collegium Pharmaceutical Inc's profitability ratios have shown varying trends over the past five years. The gross profit margin has generally been strong, increasing from 34.73% in 2019 to 83.27% in 2023, indicating the company's ability to control its production costs and generate a higher margin on its products.
The operating profit margin has also improved significantly, from -8.00% in 2019 to 29.46% in 2023. This shows that the company has been able to enhance its operational efficiency and control its operating expenses more effectively.
The pretax margin has shown a mixed performance, fluctuating between negative and positive figures over the years. It improved from -7.66% in 2019 to 13.36% in 2023, indicating that the company's ability to generate profits before taxes has strengthened.
The net profit margin has also demonstrated improvement, especially compared to the negative figure in 2019. It increased from -7.66% in 2019 to 8.50% in 2023, indicating that the company has become more profitable after accounting for all costs and taxes.
Overall, Collegium Pharmaceutical Inc's profitability ratios reflect a positive trend, with improvements in gross profit margin, operating profit margin, pretax margin, and net profit margin over the five-year period. These improvements suggest that the company has made strides in enhancing its operational efficiency and financial performance.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 14.60% | 2.84% | 2.55% | 8.73% | -7.75% |
| Return on assets (ROA) | 4.21% | -2.13% | 10.33% | 4.16% | -7.42% |
| Return on total capital | 23.42% | 4.69% | 4.36% | 14.27% | -22.94% |
| Return on equity (ROE) | 24.64% | -12.83% | 35.24% | 14.38% | -25.99% |
Collegium Pharmaceutical Inc's profitability ratios have shown varying performance over the past five years.
1. Operating return on assets (Operating ROA):
- The Operating ROA has been improving steadily over the years, from -7.75% in 2019 to 14.60% in 2023. This indicates that the company has been more efficient in generating operating income relative to its total assets.
2. Return on assets (ROA):
- The ROA has fluctuated, with a negative performance in 2019 and 2022, but generally showing positive trends over the years. The ROA was 4.21% in 2023, signifying the company's ability to generate earnings from its assets.
3. Return on total capital:
- Return on total capital has also shown improvement, reaching 19.36% in 2023 from a negative figure in 2019. This ratio reflects the company's ability to generate returns for both equity and debt holders.
4. Return on equity (ROE):
- The ROE has displayed a mixed performance, with negative figures in 2019 and 2020, followed by a significant improvement in subsequent years. In 2023, the ROE stood at 24.64%, indicating a strong profitability relative to shareholders' equity.
Overall, Collegium Pharmaceutical Inc's profitability ratios have demonstrated positive trends in recent years, suggesting enhanced efficiency in utilizing assets and generating returns for investors.